ReviewBiology2022
Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review.
Review in Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 120 citations in OpenAlex.
- Association between maternal epicardial adipose tissue, gestational diabetes mellitus, and pregnancy-related hypertensive disorders: a systematic review and meta-analysis.Archives of gynecology and obstetrics · 2023Pooled it
- Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis.Cardiovascular diabetology · 2023Pooled it
- Association of epicardial adipose tissue with the severity and adverse clinical outcomes of COVID-19: A meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes.Cardiovascular diabetology · 2023Trial
- Mediastinal adipose tissue as an active player in cardiovascular disease: a multimodality imaging narrative review.Quantitative imaging in medicine and surgery · 2026Review
- Structural and functional evolution of IL-1 targeting: From systemic neutralization to bioengineered nanotherapies.Materials today. Bio · 2026Review
- Left atrial epicardial adipose tissue volume quantification by CMR aids identification of patients at low risk for left atrial cardiomyopathy.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- The Volume and Density of Epicardial Adipose Tissue Measured by Computed Tomography as Markers of the Effects of Cardiovascular Disease Risk Factors.Journal of cardiovascular development and disease · 2026Article
- Review
- Epicardial adipose tissue in coronary microvascular disease.American heart journal plus : cardiology research and practice · 2026Review
- Elevated asprosin levels in epicardial adipose tissue: Implications for coronary artery disease.Journal of cardiovascular and thoracic research · 2026Article
- Predictive value of left atrial diameter and epicardial adipose tissue in sleep apnea and heart failure with preserved ejection fraction.Frontiers in cardiovascular medicine · 2026Article
- Aging epicardial adipose tissue: a metabolic-endocrine network driving vascular calcification.Frontiers in endocrinology · 2026Review
- Epicardial Adipocytes in Cardiac Pathology and Healing.Cardiovascular drugs and therapy · 2025Review
- Deep learning-based quantification of epicardial adipose tissue volume from non-contrast computed tomography images: a multi-centre study.European heart journal. Digital health · 2025Article
- Epicardial adipose tissue as an independent predictor of long-term outcome in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- A narrative review of epicardial adipose tissue as a predictor of cardiometabolic risk in rheumatoid arthritis patients.Annals of translational medicine · 2025Review
- Obesity as a Multifactorial Chronic Disease: Molecular Mechanisms, Systemic Impact, and Emerging Digital Interventions.Current issues in molecular biology · 2025Review
- Chest CT-based analysis of radiomic and volumetric differences in epicardial adipose tissue in HFrEF patients with and without AF.BMC cardiovascular disorders · 2025Article
- Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) are the leading causes of death worldwide. Epicardial adipose tissue (EAT) is defined as a fat depot localized between the myocardial surface and the visceral layer of the pericardium and is a type of visceral fat. EAT is one of the most important risk factors for atherosclerosis and cardiovascular events and a promising new therapeutic target in CVDs. In health conditions, EAT has a protective function, including protection against hypothermia or mechanical stress, providing myocardial energy supply from free fatty acid and release of adiponectin. In patients with obesity, metabolic syndrome, or diabetes mellitus, EAT becomes a deleterious tissue promoting the development of CVDs. Previously, we showed an adverse modulation of gene expression in pericoronary adipose tissue in patients with coronary artery disease (CAD). Here, we summarize the currently available evidence regarding the role of EAT in the development of CVDs, including CAD, heart failure, and atrial fibrillation. Due to the rapid development of the COVID-19 pandemic, we also discuss data regarding the association between EAT and the course of COVID-19. Finally, we present the potential therapeutic possibilities aiming at modifying EAT's function. The development of novel therapies specifically targeting EAT could revolutionize the prognosis in CVDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.